A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety,
tolerability, PK, pharmacodynamics, PGx, and efficacy of fadraciclib administered orally BID.
This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors
and lymphoma who have progressed despite having standard therapy or for which no standard
therapy exists.